Cochrane · systematic review · CD005555
Lens extraction for chronic angle‐closure glaucoma
Ong, AY, Ng, SM, Vedula, SS, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
Eyes and VisionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
30
current version
GRADE rated
18
No studies
11
Included studies
NR
No studies 11 · 36.7%Ungraded 1 · 3.3%Very low 0 · 0%Low 10 · 33.3%Moderate 8 · 26.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Phacoemulsification compared with laser peripheral iridotomy for primary angle‐closure glaucoma
Population: participants with primary angle‐closure glaucoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Progression of visual field loss (worsening of one or more stages, accordingto the Glaucoma Staging System‐2) (at 12 months) Phacoemulsification vs laser peripheral iridotomy | OR 0.35 [0.13, 0.91] | NR | Moderate Downgraded: imprecision |
Mean IOP change from baseline to 12 months (mmHg) Phacoemulsification vs laser peripheral iridotomy | no estimate extracted | NR | Moderate Downgraded: imprecision |
Mean number of medications to control IOP (at 12 months) Phacoemulsification vs laser peripheral iridotomy | no estimate extracted | NR | Moderate Downgraded: imprecision |
Gonioscopic findings (Degree of angle closure) (at 12 months or later) Phacoemulsification vs laser peripheral iridotomy | no estimate extracted | NR | Moderate Downgraded: imprecision |
Visual acuity (ETDRS letter chart) (at 12 months) Phacoemulsification vs laser peripheral iridotomy | no estimate extracted | NR | Moderate Downgraded: imprecision |
Adverse effects Phacoemulsification vs laser peripheral iridotomy | no estimate extracted | NR | No studies |
Quality of life measures(measured on the EQ‐5D; higher = better) (at 12 months) Phacoemulsification vs laser peripheral iridotomy | no estimate extracted | NR | Moderate Downgraded: imprecision |
Phacoemulsification versus phacoemulsification plus viscogonioplasty for primary angle‐closure glaucoma
Population: participants with primary angle‐closure glaucoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Progression of visual field loss Phacoemulsification vs phacoemulsification plus viscogonioplasty | no estimate extracted | NR | No studies |
Mean IOP change from baseline to 12 months (mmHg) Phacoemulsification vs phacoemulsification plus viscogonioplasty | no estimate extracted | 91 participants | Low Downgraded: risk of bias, imprecision |
Mean number of medications to control IOP (at 12 months) Phacoemulsification vs phacoemulsification plus viscogonioplasty | no estimate extracted | 91 participants | Low Downgraded: risk of bias, imprecision |
Gonioscopic findings (Spaeth grading system) (at 12 months or later) Phacoemulsification vs phacoemulsification plus viscogonioplasty | no estimate extracted | 91 participants | Low Downgraded: risk of bias, imprecision |
Gonioscopic findings (TISA500) (at 12 months) Phacoemulsification vs phacoemulsification plus viscogonioplasty | no estimate extracted | 91 participants | Low Downgraded: risk of bias, imprecision |
Gonioscopic findings (TISA750) (at 12 months) Phacoemulsification vs phacoemulsification plus viscogonioplasty | no estimate extracted | 91 participants | Low Downgraded: risk of bias, imprecision |
Visual acuity (log MAR units) (postoperatively) Phacoemulsification vs phacoemulsification plus viscogonioplasty | no estimate extracted | 91 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects (at 12 months) Phacoemulsification vs phacoemulsification plus viscogonioplasty | no estimate extracted | NR | No studies |
Quality of life measures Phacoemulsification vs phacoemulsification plus viscogonioplasty | no estimate extracted | NR | No studies |
Phacoemulsification versus phacoemulsification plus goniosynechialysis for primary angle‐closure glaucoma
Population: participants with primary angle closure glaucoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Progression of visual field loss Phacoemulsification vs phacoemulsification plus goniosynechialysis | no estimate extracted | NR | No studies |
Mean IOP change from baseline (mmHg) (at 12 months) Phacoemulsification vs phacoemulsification plus goniosynechialysis | no estimate extracted | 32 participants | Moderate Downgraded: imprecision |
Mean number of medications to control IOP (at 12 months) Phacoemulsification vs phacoemulsification plus goniosynechialysis | no estimate extracted | 32 participants | Moderate Downgraded: imprecision |
Gonioscopic findings (Anterior segment optical coherence tomography parameters) (at 6 months) Phacoemulsification vs phacoemulsification plus goniosynechialysis | no estimate extracted | 64 participants | Ungraded |
Visual acuity (log MAR units) Phacoemulsification vs phacoemulsification plus goniosynechialysis | no estimate extracted | NR | No studies |
Adverse effects (at 6 months) Phacoemulsification vs phacoemulsification plus goniosynechialysis | no estimate extracted | NR | No studies |
Quality of life measures Phacoemulsification vs phacoemulsification plus goniosynechialysis | no estimate extracted | NR | No studies |
Phacoemulsification versus phacoemulsification plus trabeculectomy for primary angle‐closure glaucoma
Population: participants with primary angle‐closure glaucoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Progression of visual field loss (at 12 months) Phacoemulsification vs phacoemulsification plus trabeculectomy | no estimate extracted | NR | No studies |
Mean IOP change from baseline to 12 months (mmHg) Phacoemulsification vs phacoemulsification plus trabeculectomy | no estimate extracted | 63 participants | Low Downgraded: risk of bias, imprecision |
Mean number of medications to control IOP (at 12 months) Phacoemulsification vs phacoemulsification plus trabeculectomy | no estimate extracted | 63 participants | Low Downgraded: risk of bias, imprecision |
Gonioscopic findings Phacoemulsification vs phacoemulsification plus trabeculectomy | no estimate extracted | NR | No studies |
Mean best corrected visual acuity (on Snellen chart) (at final Phacoemulsification vs phacoemulsification plus trabeculectomy | no estimate extracted | 63 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects (up to 12 months) Phacoemulsification vs phacoemulsification plus trabeculectomy | RR 0.59 [0.34, 1.04] | 63 participants | Low Downgraded: risk of bias, imprecision |
Quality of life measures (at 12 months) Phacoemulsification vs phacoemulsification plus trabeculectomy | no estimate extracted | NR | No studies |